Impax Asset Management Group plc Grows Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Impax Asset Management Group plc increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 753,666 shares of the medical research company's stock after buying an additional 80,567 shares during the quarter. Thermo Fisher Scientific comprises 1.6% of Impax Asset Management Group plc's investment portfolio, making the stock its 12th biggest holding. Impax Asset Management Group plc owned about 0.20% of Thermo Fisher Scientific worth $399,194,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Savant Capital LLC boosted its position in shares of Thermo Fisher Scientific by 0.5% in the fourth quarter. Savant Capital LLC now owns 3,627 shares of the medical research company's stock worth $1,997,000 after buying an additional 18 shares during the period. 1776 Wealth LLC boosted its position in shares of Thermo Fisher Scientific by 2.4% in the fourth quarter. 1776 Wealth LLC now owns 799 shares of the medical research company's stock worth $440,000 after buying an additional 19 shares during the period. Sugarloaf Wealth Management LLC boosted its position in shares of Thermo Fisher Scientific by 6.9% in the fourth quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company's stock worth $156,000 after buying an additional 19 shares during the period. Rosenberg Matthew Hamilton boosted its position in shares of Thermo Fisher Scientific by 3.7% in the fourth quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company's stock worth $279,000 after buying an additional 19 shares during the period. Finally, Tsfg LLC boosted its position in shares of Thermo Fisher Scientific by 8.3% in the fourth quarter. Tsfg LLC now owns 249 shares of the medical research company's stock worth $132,000 after buying an additional 19 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Raymond James lifted their price objective on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an "outperform" rating in a research report on Thursday, February 1st. Wolfe Research assumed coverage on Thermo Fisher Scientific in a research report on Wednesday, December 13th. They set an "outperform" rating and a $575.00 price objective for the company. Evercore ISI lifted their price objective on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an "outperform" rating in a research report on Thursday, April 4th. Citigroup initiated coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They set a "neutral" rating and a $620.00 target price on the stock. Finally, Royal Bank of Canada raised their target price on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an "outperform" rating in a report on Thursday, February 1st. Five investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus target price of $599.00.

Thermo Fisher Scientific Stock Up 1.8 %

NYSE TMO traded up $10.44 on Tuesday, reaching $589.24. The company had a trading volume of 1,026,296 shares, compared to its average volume of 1,566,822. The firm has a market capitalization of $224.68 billion, a price-to-earnings ratio of 38.14, a price-to-earnings-growth ratio of 2.44 and a beta of 0.80. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The company's fifty day moving average is $570.26 and its 200-day moving average is $524.68.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping analysts' consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The company had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. During the same period in the prior year, the business posted $5.40 EPS. The company's quarterly revenue was down 4.9% on a year-over-year basis. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Stockholders of record on Friday, March 15th will be paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.26%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.35. The ex-dividend date is Thursday, March 14th. Thermo Fisher Scientific's dividend payout ratio is currently 10.10%.

Insider Transactions at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 14,566 shares of the firm's stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, SVP Michael A. Boxer sold 14,566 shares of the firm's stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The disclosure for this sale can be found here. Insiders sold a total of 50,277 shares of company stock worth $28,513,384 in the last three months. Insiders own 0.32% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.